Effects of Oral Nicotine and Caffeine Pouches on Anaerobic Performance, Autonomic Function, Cognition, and Behavior
Launched by UNIVERSITY OF SOUTHERN MISSISSIPPI · Jul 25, 2024
Trial Information
Current as of July 01, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
No description provided
Gender
MALE
Eligibility criteria
- Inclusion Criteria:
- • Being 21 to 40 years of age
- • Being biologically male
- • Having a body mass index (BMI) of \< 30 kilograms/meter-squared
- • Participating in moderate/vigorous exercise for at least 150 minutes/week over the last month
- Exclusion Criteria:
- • individuals who are younger than 21 or older than 40
- • missing any limbs or part of a limb
- • having any neuromuscular/musculoskeletal injury or impairment that would prevent performing any exercise/functional measures for this study
- • having a pacemaker or any other electrical implant
- • a diagnosis (defined as the presence of disease of or using medication to treat the disease) of heart failure, cardiomyopathy (dilated or hypertrophic), valvular disease, type I or type II diabetes
- • taking insulin injections
- • any history of severe or mild traumatic brain injury within the last two years
- • kidney, liver, thyroid, or heart disease
- • treated or untreated American Heart Association stage 2 hypertension (\>140 millimeters of mercury / \> 90 millimeters of mercury)
- • any diagnosed neurological or neurodegenerative diseases
- • having donated blood or plasma in the last 20 days prior to blood collection procedures
- • taking any supplements/medications that may interfere with the results of the study
- • any surgeries that would impact swallowing and/or digestion
- • currently smoking, vaping, using e-cigarettes, or using any other combustible/smokeless tobacco products
- • using smokeless tobacco-free nicotine products on more than 2 days/week
- • daily caffeine use of more than 250 milligrams/day or use of any oral caffeine pouches
- • have allergies or are regularly taking medications that would impact this study and/or negatively interact with caffeine or nicotine.
About University Of Southern Mississippi
The University of Southern Mississippi is a prominent academic institution dedicated to advancing research and education in various fields, including healthcare and clinical studies. As a clinical trial sponsor, the university leverages its extensive resources and expertise to facilitate innovative research initiatives aimed at improving patient outcomes and enhancing medical knowledge. Committed to ethical standards and rigorous scientific methodologies, the University of Southern Mississippi fosters collaboration among researchers, healthcare professionals, and the community to address critical health challenges and contribute to the advancement of evidence-based practices.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Hattiesburg, Mississippi, United States
Patients applied
Trial Officials
Austin J Graybeal, PhD
Principal Investigator
University of Southern Mississippi
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported